Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Janssen/Legend’s Cilta-Cel Responses Could Make Up For Second-To-Market Position

Mitigation Strategy Lessens Neurotoxicity Of CAR-T In Myeloma

Executive Summary

Cilta-cel likely will be the second BCMA-targeting CAR-T therapy approved in the US for multiple myeloma, but appears to have an efficacy advantage over BMS/bluebird’s first-to-market Abecma.

You may also be interested in...



Janssen/Legend Plan Phased US Launch For BCMA-Targeting CAR-T Carvykti

Janssen priced the one-time autologous treatment at $465,000, well above the $419,500 list price for Bristol’s first-to-market CAR-T, but expects broad commercial and Medicare coverage. 

Janssen/Legend’s Cilta-Cel Consistent In Earlier Myeloma, Longer-Term Results

The partners reported initial data at ASH for their BCMA-targeting CAR-T therapy in second-line multiple myeloma that appear consistent with longer-term results and ahead of their main competitor, Bristol’s Abecma.

From Auto To Allo: Poseida Tries To Pick The Winning CAR-T Team

The company is winding down its autologous myeloma CAR-T program as competition in that market heats up and interest in off-the-shelf CAR-Ts grows.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144473

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel